Mitophagy has also been found to contribute to increased drug resistance in CSCs, and silencing BNIP3L can significantly inhibit mitophagy by enhancing the degree of sensitivity of colorectal CSCs to DXR [122]; whereas BNIP3L-dependent mitophagy promoted HBx-induced enhancement of hepatocellular carcinoma stem cell activity [123]. Here, BNIP3L is linked to hepatocellular carcinoma.